Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Jazz (JAZZ) Climb 41% to Reach the Level Wall Street Analysts Expect?

The biotech was beaten down despite a highly promising future.

Why Jazz Pharmaceuticals Sank 23% in 2021

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Jazz (JAZZ): Can Its 9% Jump Turn into More Strength?

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5 billion in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin1 improvement from 2021 to 2025, driven by operational excellence.

Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader

DUBLIN , Jan. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind, randomized withdrawal study of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adults with idiopathic hypersomnia were published online in The Lancet Neurology. The results of the Phase 3 clinical trial showed clinically meaningful and statistically significant differences with Xywav compared to placebo in the primary endpoint of change in the Epworth Sleepiness Scale (ESS) score and key secondary endpoints, which included measures that assessed patients' perceptions of the changes in their idiopathic hypersomnia overall (PGIc), symptom severity, including excessive daytime sleepiness (EDS), sleep inertia and prolonged sleep duration (Idiopathic Hypersomnia Severity Scale), and improved daytime performance.1  In August 2021, Xywav became the first and only drug approved for patients with idiopathic hypersomnia by the U.S. Food and Drug Administration (FDA).2 Xywav for idiopathic hypersomnia was made commercially available in November 2021.

Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

Acadia Healthcare

Eli Lilly

Pfizer

Health care stocks to watch as coronavirus cases show no signs of slowing down.

Top Stocks To Invest In 2022? 4 Health Care Stocks To Check Out

The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.

JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia

DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, from 2:15 – 2:55 p.m.

Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of idiopathic hypersomnia in adults, making it the second ODE for the medication following the exclusivity granted in the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. As Jazz was the first sponsor to obtain FDA approval for idiopathic hypersomnia, Xywav will have seven-year market exclusivity for this indication from its FDA approval on August 12, 2021.

U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.

Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study

Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder. JZP150 is designed to address the underlying cause of PTSD and patients' associated symptoms such as anxiety, insomnia and nightmares.

Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD

DUBLIN, Dec. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients' associated symptoms (anxiety, insomnia and nightmares).

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder

The company recently announced annual revenue of $2.9 billion, with an adjusted earning per share of $12.46.

Breaking into the Cannabis industry with strength

Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase IIb study to evaluate JZP385 for essential tremor.

Jazz (JAZZ) Enrols First Patient in Essential Tremor Study

DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), a highly selective modulator of T-type calcium channels in development for the potential treatment of moderate to severe essential tremor (ET).1 The multicenter, double-blind, randomized, placebo-controlled trial will evaluate adults with moderate to severe ET treated with a once-daily oral capsule of suvecaltamide or placebo. ET is the most common movement disorder, yet a new pharmacotherapy has not been approved for the underlying cause of the disorder in more than 50 years.2,3,4 "Currently, patients with ET are treated with drugs that were not developed for this specific disorder.

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

Caterpillar

Copa Hlds

DTE Energy

Roku

United States Steel

Lockheed Martin

These seven meme stocks suffered downturns recently, but they have the appropriate catalysts to move upward in the near term. The post 7 Meme Stocks to Buy on Their Market Slump and Rebound appeared first on InvestorPlace.

7 Meme Stocks to Buy on Their Market Slump and Rebound

Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). In Cohort 1c, a dosing regimen of Rylaze administered 25 mg on Monday and Wednesday and 50 mg on Friday demonstrated a favorable benefit-to-risk profile, showing that Rylaze maintains a clinically meaningful level of nadir serum asparaginase activity at both 48 and 72 hours.

Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting

MADRID and DUBLIN, Dec. 13, 2021 /PRNewswire/ -- PharmaMar (MSE: PHM) and partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed small cell lung cancer (SCLC). The trial will measure overall survival (OS) as the primary endpoint and progression-free survival (PFS) as a secondary endpoint of lurbinectedin monotherapy or lurbinectedin in combination with irinotecan compared with investigator's choice of topotecan or irinotecan, in patients with SCLC whose disease has progressed following prior platinum-containing chemotherapy with or without anti-PD-1 or anti-PD-L1 agents.

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

DUBLIN, Dec. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity or silent inactivation to an E. coli-derived asparaginase.

Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting

Beyond Meat

DocuSign

Now is a good time to be greedy and buy up these depressed stocks.

3 High-Growth Stocks That Are Screaming Buys in December

Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.

Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC

DUBLIN, Dec. 1, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex ® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL. "With the successful integration of GW Pharmaceuticals this year, Jazz is excited to present at the AES meeting for the first time and meet with physicians and patient advocacy groups to better understand patient needs and build on GW's progress in epilepsy," said Robert Iannone, M.D.

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting

DUBLIN, Nov. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq® (atezolizumab) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, IMforte, conducted in collaboration with F.

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer

Innovative Industrial Properties

There might not be a better time to buy these three cannabis stocks than right now.

News for Jazz Pharmaceuticals Stock (JAZZ)